


Product Name : Trilaciclib hydrochloride
Cat. No. : PC-60396
CAS No. : 1977495-97-8
Molecular Formula : C₂₄H₃₂Cl₂N₈O
Molecular Weight : 519.47
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



Biological Activity

Trilaciclib (G1T28) hydrochloride is a potent and selective inhibitor of **CDK4/6** with biochemical IC₅₀ of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.

Trilaciclib (G1T28) displays >30-fold selectivity for CDK4/cyclin D1 over CDK2/cyclin A, CDK2/cyclin E, CDK5/p25, CDK5/p35, and CDK7/cyclin H/Mat1, 50-fold over CDK9/cyclin T.

Trilaciclib (G1T28) reversibly pauses the cell cycle in the G1 phase in CDK4/6-dependent cell lines, protects CDK4/6-dependent cells from chemotherapy-induced damage in vitro.

Trilaciclib (G1T28) induces a reversible cell-cycle arrest in murine and canine HSPCs; attenuates chemotherapy-induced myelosuppression in vivo.

References

Bisi JE, et al. Mol Cancer Ther. 2016 May;15(5):783-93.

He S, et al. Sci Transl Med. 2017 Apr 26;9(387). pii: eaal3986.

Stice JP, et al. Mol Cancer Res. 2017 Jun;15(6):660-669.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com